Literature DB >> 16433766

Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.

R Borrows1, G Chusney, M Loucaidou, A James, J Lee, J V Tromp, J Owen, T Cairns, M Griffith, N Hakim, A McLean, A Palmer, V Papalois, D Taube.   

Abstract

Studies of renal transplantation utilizing trough plasma level monitoring of mycophenolic acid (MPA) have shown inconsistent associations with toxicity and rejection. In this study, 5600 12-h trough MPA samples from 121 renal transplant recipients immunosuppressed with mycophenolate mofetil (MMF) and tacrolimus in a steroid sparing protocol (steroids for 7 days only) were sequentially analyzed. Higher MPA levels were associated with lower hemoglobin concentrations and anemia (hemoglobin <10 g/dL). Similarly, higher MPA levels were associated with lower total white cell counts and an increased incidence of leucopenia (total white cell count <4.0 x 10(9)/L). Hypoalbuminemia and renal impairment were also associated with hemotoxicity. MMF-associated diarrhea and viral infection were associated with higher MPA levels. Conversely, biopsy-proven acute rejection within the first month post-transplantation was associated with lower MPA levels. Anti-CD25 antibody induction was also associated with reduced rejection rates. No association was seen between MPA levels and platelet count, thrombocytopenia or bacterial infection. An MPA level of 1.60 mg/L early post-transplantation best discriminated patients with and without rejection, and an MPA level of 2.75 mg/L best discriminated patients with and without toxicity later post-transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433766     DOI: 10.1111/j.1600-6143.2005.01151.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  27 in total

1.  The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients.

Authors:  Zhang Wei Xia; Chen Yong Jun; Chen Hao; Chen Bing; Shi Min Min; Xie Jun Jie
Journal:  Eur J Clin Pharmacol       Date:  2010-05-15       Impact factor: 2.953

2.  Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients.

Authors:  Marc Labriffe; Julien Vaidie; Caroline Monchaud; Jean Debord; Pascal Turlure; Stephane Girault; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

3.  Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway.

Authors:  Arjang Djamali; Aparna Vidyasagar; Gokhan Yagci; Ling-Jin Huang; Shannon Reese
Journal:  Transplantation       Date:  2010-08-27       Impact factor: 4.939

4.  Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.

Authors:  Pauline Lancia; Beate Aurich; Phuong Ha; Anne Maisin; Véronique Baudouin; Evelyne Jacqz-Aigrain
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 5.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 6.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

7.  Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.

Authors:  L'aurelle A Johnson; William S Oetting; Saonli Basu; Susie Prausa; Arthur Matas; Pamala A Jacobson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-21       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

9.  Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-03       Impact factor: 5.742

Review 10.  Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.

Authors:  J Michael Tredger; Nigel W Brown; Anil Dhawan
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.